TIRZ · 20 mg / vial
Tirzepatide
$145 AUD
In stockDual GIP/GLP-1 agonist — studied for strong appetite control, fat loss and blood-sugar stability.
- Purity
- ≥ 99.3%
- Dose
- 20 mg / vial
- Form
- Lyophilized
- QC
- HPLC + MS
What it does
Tirzepatide is a dual agonist that activates both the GLP-1 and GIP receptors, the two incretin pathways most involved in appetite regulation and insulin response. In clinical research it has produced large, sustained reductions in body weight alongside substantial improvements in glycaemic control, making it the most-studied dual incretin peptide currently available.
How it works in the body
It pulls two levers at once: one tells your brain you're full sooner and keeps you fuller for longer, the other helps your body release insulin at the right time so sugar gets used instead of stored. Together that means smaller appetite, steadier energy and steady fat loss.
Researched benefits
- Substantial, sustained body-weight and waist reduction in trial subjects
- Strong improvements in fasting glucose and HbA1c
- Reduced appetite, food noise and earlier meal satiety
- Improved triglycerides, blood pressure and liver fat markers
- Once-weekly dosing with a smooth, predictable titration
Typical research protocol
- Reconstitution
- Add 2 mL bacteriostatic water to the 20 mg vial → 10 mg/mL (1 pen unit = 0.1 mg / 100 mcg).
- Dose
- Typical research titration: 2.5 mg → 5 mg → 7.5 mg → 10 mg weekly, stepping up every 4 weeks as tolerated.
- Pen units (U-100)
- At 10 mg/mL: 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units on a U-100 peptide pen.
- Frequency
- Once weekly, same day each week.
Recommended: use a single-use, sterile drawing syringe and needle for reconstitution — available in the accessories section.
For in-vitro research only — not for human or veterinary consumption.
Potential side effects
- Nausea, vomiting, diarrhoea or constipation — dose-dependent and most common
- Decreased appetite, early satiety, burping and reflux
- Fatigue, headache and dizziness
- Injection-site reactions
- Delayed gastric emptying; hypoglycaemia risk rises if combined with insulin-secreting agents
Reported in published literature and research reports. Not exhaustive and not medical advice — this product is supplied for laboratory research only.
Deep dive · properties
The nerdy details 🔬
- Half-life
- ~5 days (supports once-weekly dosing)
- Sequence / class
- 39-residue dual GIP/GLP-1 receptor agonist (LY3298176)
- Molecular weight
- ≈ 4,814 Da
- Origin
- Phase-3 obesity data published 2022 (SURMOUNT-1)
- Storage & stability
- Store lyophilized vials at –20 °C for long-term storage (up to 24 months). Once reconstituted, refrigerate at 2–8 °C and use within 28 days. Protect from light and freeze/thaw cycles.
Common questions
Wait, quick question. 🙋
How does tirzepatide differ from retatrutide?
Tirzepatide is a dual agonist (GLP-1 + GIP). Retatrutide adds a third receptor — glucagon — which appears to drive additional fat-loss and liver-fat effects in phase-2 data.
Why titrate slowly?
Stepping up every 4 weeks lets gastrointestinal tolerance build. Most research protocols start at 2.5 mg weekly and only increase if the prior step was well tolerated.
Published research
Where the data lives 📚
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) ↗
New England Journal of Medicine, 2022
Linked purely for research context. Sold for laboratory use only.
Tirzepatide
$145 AUD · 20 mg / vial
Research use only · Not for human or veterinary consumption